294 related articles for article (PubMed ID: 24473196)
1. STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes.
Xiang M; Birkbak NJ; Vafaizadeh V; Walker SR; Yeh JE; Liu S; Kroll Y; Boldin M; Taganov K; Groner B; Richardson AL; Frank DA
Sci Signal; 2014 Jan; 7(310):ra11. PubMed ID: 24473196
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA circuits regulate the cancer-inflammation link.
Iliopoulos D
Sci Signal; 2014 Mar; 7(318):pe8. PubMed ID: 24667374
[TBL] [Abstract][Full Text] [Related]
3. DNA damage induces NF-κB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion.
Niu J; Shi Y; Tan G; Yang CH; Fan M; Pfeffer LM; Wu ZH
J Biol Chem; 2012 Jun; 287(26):21783-95. PubMed ID: 22547075
[TBL] [Abstract][Full Text] [Related]
4. Kaposi's sarcoma herpesvirus (KSHV) microRNA K12-1 functions as an oncogene by activating NF-κB/IL-6/STAT3 signaling.
Chen M; Sun F; Han L; Qu Z
Oncotarget; 2016 May; 7(22):33363-73. PubMed ID: 27166260
[TBL] [Abstract][Full Text] [Related]
5. Impact of miR-223-3p and miR-2909 on inflammatory factors IL-6, IL-1ß, and TNF-α, and the TLR4/TLR2/NF-κB/STAT3 signaling pathway induced by lipopolysaccharide in human adipose stem cells.
Wu J; Niu P; Zhao Y; Cheng Y; Chen W; Lin L; Lu J; Cheng X; Xu Z
PLoS One; 2019; 14(2):e0212063. PubMed ID: 30807577
[TBL] [Abstract][Full Text] [Related]
6. The inflammatory/cancer-related IL-6/STAT3/NF-κB positive feedback loop includes AUF1 and maintains the active state of breast myofibroblasts.
Hendrayani SF; Al-Harbi B; Al-Ansari MM; Silva G; Aboussekhra A
Oncotarget; 2016 Jul; 7(27):41974-41985. PubMed ID: 27248826
[TBL] [Abstract][Full Text] [Related]
7. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer.
Iliopoulos D; Jaeger SA; Hirsch HA; Bulyk ML; Struhl K
Mol Cell; 2010 Aug; 39(4):493-506. PubMed ID: 20797623
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-30c-2-3p negatively regulates NF-κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer.
Shukla K; Sharma AK; Ward A; Will R; Hielscher T; Balwierz A; Breunig C; Münstermann E; König R; Keklikoglou I; Wiemann S
Mol Oncol; 2015 Jun; 9(6):1106-19. PubMed ID: 25732226
[TBL] [Abstract][Full Text] [Related]
9. NF-κB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma.
McFarland BC; Hong SW; Rajbhandari R; Twitty GB; Gray GK; Yu H; Benveniste EN; Nozell SE
PLoS One; 2013; 8(11):e78728. PubMed ID: 24244348
[TBL] [Abstract][Full Text] [Related]
10. miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8.
Hu N; Zhang J; Cui W; Kong G; Zhang S; Yue L; Bai X; Zhang Z; Zhang W; Zhang X; Ye L
J Biol Chem; 2011 Apr; 286(15):13714-22. PubMed ID: 21343296
[TBL] [Abstract][Full Text] [Related]
11. IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation.
Zhang F; Wang B; Qin T; Wang L; Zhang Q; Lu Y; Song B; Yu X; Li L
Mol Cell Biochem; 2020 Oct; 473(1-2):1-13. PubMed ID: 32602014
[TBL] [Abstract][Full Text] [Related]
12. NF-κB signaling relieves negative regulation by miR-194 in hepatocellular carcinoma by suppressing the transcription factor HNF-1α.
Bao C; Li Y; Huan L; Zhang Y; Zhao F; Wang Q; Liang L; Ding J; Liu L; Chen T; Li J; Yao M; Huang S; He X
Sci Signal; 2015 Jul; 8(387):ra75. PubMed ID: 26221053
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of miRNAs regulating NF-κB and STAT3 crosstalk during colitis-associated tumorigenesis.
El-Daly SM; Omara EA; Hussein J; Youness ER; El-Khayat Z
Mol Cell Probes; 2019 Oct; 47():101442. PubMed ID: 31479716
[TBL] [Abstract][Full Text] [Related]
14. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.
Rozovski U; Harris DM; Li P; Liu Z; Jain P; Veletic I; Ferrajoli A; Burger J; Thompson P; Jain N; Wierda W; Keating MJ; Estrov Z
Int J Cancer; 2017 Nov; 141(10):2076-2081. PubMed ID: 28722170
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.
Keklikoglou I; Koerner C; Schmidt C; Zhang JD; Heckmann D; Shavinskaya A; Allgayer H; Gückel B; Fehm T; Schneeweiss A; Sahin O; Wiemann S; Tschulena U
Oncogene; 2012 Sep; 31(37):4150-63. PubMed ID: 22158050
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of EGFR and IL-6-STAT3 signalling by miR-146b: a potential targeted therapy for epithelial ovarian cancer.
Yan M; Han M; Yang X; Shen R; Wang H; Zhang L; Xia S; Yang P; Zhai G; Shao Q
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1905-1915. PubMed ID: 34369236
[TBL] [Abstract][Full Text] [Related]
17. Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration.
Snyder M; Huang XY; Zhang JJ
J Biol Chem; 2011 Nov; 286(45):38886-93. PubMed ID: 21937440
[TBL] [Abstract][Full Text] [Related]
18. JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway.
Fang J; Chu L; Li C; Chen Y; Hu F; Zhang X; Zhao H; Liu Z; Xu Q
Oncol Rep; 2015 Jan; 33(1):494-502. PubMed ID: 25405520
[TBL] [Abstract][Full Text] [Related]
19. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
Esparza-López J; Alvarado-Muñoz JF; Escobar-Arriaga E; Ulloa-Aguirre A; de Jesús Ibarra-Sánchez M
BMC Cancer; 2019 Jul; 19(1):728. PubMed ID: 31337349
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
